Marianne Grønlie Guren
机构: MD PhD, Oslo University Hospital
每年引用次数
引用次数
引用: 7,461
H-指数: 42
I10-指数 : 81
出版物: 182
Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.
Anne Hansen Ree , Hanne Hamre , Christian Kersten , Eva Hofsli
Journal of Clinical Oncology 39 ( 15_suppl) 3556 -3556
18
2021
FAGLIGE ANBEFALINGER for strålebehandling ved øsofaguscancer (spiserørskreft)
Gunilla Frykholm , Lise Balteskard UNN , Nils Glenjen HUS , Marianne Grønlie Guren
1
2011
How do Norwegian oncologists perceive their working conditions?
Kirsten Marienhagen , Aslaug Helland , Terje Nordberg , Marianne Grønlie Guren
Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin, ny Raekke 130 ( 5) 487 -489
1
2010
Early radiologic signal of nivolumab responsiveness after short-course oxaliplatin-based chemotherapy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
Sebastian Meltzer , Anne Negård , Hanne Mari Hamre , Christian Kersten
Cancer Research 82 ( 12_Supplement) 1279 -1279
2022
FAGLIGE ANBEFALINGER for behandling ved analcancer
Gunilla Frykholm , Lise Balteskard UNN , Olav Dahl HUS , Marianne Grønlie Guren
Leder av referansegruppen, NGICG-CR Direktør, Kreftregisteret
Marianne Grønlie Guren , Giske Ursin
Changes in colorectal cancer incidence in seven high-income countries: a population-based study
Marzieh Araghi , Isabelle Soerjomataram , Aude Bardot , Jacques Ferlay
The Lancet Gastroenterology & Hepatology 4 ( 7) 511 -518
270
2019
Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer.
David N Church , Arild Nesbakken , Anita Sveen , Ragnhild A Lothe
ESMO open 5 ( 6)
2020
Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
Jørgen Smeby , Anita Sveen , Christian H Bergsland , Ina A Eilertsen
ESMO Open 4 ( 3)
5
2019
Characteristics of early-onset vs late-onset colorectal cancer: a review
REACCT Collaborative , Alexandra M Zaborowski , Ahmed Abdile , Michel Adamina
JAMA surgery 156 ( 9) 865 -874
52
2021
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
Kushtrim Kryeziu , Seyed H Moosavi , Christian H Bergsland , Marianne G Guren
Journal of Translational Medicine 19 1 -11
4
2021
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Alison Rowsell , Samantha C Sodergren , Vassilios Vassiliou , Anne-Sophie Darlington
Gastric Cancer 25 ( 4) 665 -677
1
2022
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study
Sean McPhail , Matthew E Barclay , Shane A Johnson , Ruth Swann
The Lancet Oncology 25 ( 3) 338 -351
3
2024
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
Anne Hansen Ree , Jūratė Šaltytė Benth , Hanne M Hamre , Christian Kersten
British Journal of Cancer 1 -8
2024
Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatin-based chemotherapy and immune checkpoint blockade (ICB)
Anne Hansen Ree , Paula A Bousquet , Hilde L Nilsen , Torben Lüders
Cancer Research 84 ( 6_Supplement) 2522 -2522
2024
Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial.
Anne Hansen Ree , Jūratė Šaltytė Benth , Hanne M Hamre , Christian Kersten
Journal of Clinical Oncology 41 ( 16_suppl) 3552 -3552
2023
A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers
Stephane Niyoteka , Romain-David Seban , Rahimeh Rouhi , Andrew Scarsbrook
European Journal of Nuclear Medicine and Molecular Imaging 50 ( 13) 4010 -4023
1
2023
International validation of the EORTC QLQ-ANL27, a field study to test the anal cancer-specific health-related quality-of-life questionnaire
Samantha C Sodergren , Colin D Johnson , Alexandra Gilbert , Anne-Sophie Darlington
International Journal of Radiation Oncology* Biology* Physics 115 ( 5) 1155 -1164
2
2023
Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer–The RAPIDO trial
Esmée A Dijkstra , Geke AP Hospers , Elma Meershoek-Klein Kranenbarg , Joke Fleer
Radiotherapy and Oncology 171 69 -76
35
2022
A machine-learning-based bibliometric analysis of the scientific literature on anal cancer
Pierfrancesco Franco , Eva Segelov , Anders Johnsson , Rachel Riechelmann
Cancers 14 ( 7) 1697 -1697
7
2022